ESMO 2024: Treatment of uHCC - Episode 8

Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

October 25, 2024

Richard Finn, MD, Olatunji Alese, MD, Daneng Li, MD, Anthony El-Khoueiry, MD, Masatoshi Kudo, MD, PhD, Steven Chan, MD

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

EP. 1: Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP. 2: Treatment Decisions Based on BLCL Stage

EP. 3: Current Treatment in First Line – IO + TKI or IO + IO

EP. 4: Use of monotherapy (IO or TKI) or localized treatment in First Line

EP. 5: EMERALD-1 Study Results

EP. 6: Discussion and Summary

EP. 7: LEAP-012 Study Results

Now Viewing

EP. 8: Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

EP. 9: ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

EP. 10: Choosing Second-Line Therapies: Considering First Line Therapy Received

EP. 11: Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

EP. 12: CELESTIAL Sub-Group Discussion

EP. 13: Discussion of RESORCE Trial

EP. 14: Real-World Treatment Data from the Phase 4 STELLAR Trial

EP. 15: Importance of Real-World Data in Supporting Treatment Options

EP. 16: CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment

EP. 17: Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs

Video content above is prompted by the following:

Dr Kudo: Please review the findings from the EMERALD-1 trial, assessing durvalumab ± plus or minus bevacizumab with transarterial chemoembolizationTACE in first-line1L treatment of uHCCunresectable hepatocellular carcinoma, and discuss the impact of these findings on the treatment landscape.
• 2024 American Society of Clinical Oncology (ASCO) GastroIintestinal Cancers Symposium: – PFS data (Lencioni et al., J Clin Oncol. LBA 432)
• 2024 ASCO Annual Meeting: – Ssafety analysis (Chan et al., J Clin Oncol. Abstract 4122)
• Outcomes by baseline tumor burden (Kudo, ESMO 2024 Congress, Poster Presentation 950P